Levitee Labs Enters into Credit Facility For Up To $12 Million

Quick Take: Levitee will utilize the proceeds from the Loan to support their prospective future acquisitions of several assets in the clinics, pharmacies and mental health space as well as for working capital purposes. Levitee Labs Inc. (CSE: LVT) (OTCMKTS: LVTTF), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, is pleased to […]


Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product

Quick Take: Numinus Bioscience has successfully developed PSYBINA™ from Psilocybe species using IP technology related to the production of extracts and downstream derivatives and formulations from Psychoactive Species Cultured Mycelium Numinus Wellness Inc. (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to have finalized the study design and protocol for a Phase 1 clinical trial on a naturally […]


PharmaDrug Commences Trading on the OTCQB Market in the United States

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce it has qualified for trading on the OTCQB Venture Market (the “OTCQB”) operated by the OTC Markets Group Inc. The Company’s […]

COMPASS Pathways

Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups

Quick Take: Investigator-initiated study shows remission in major depression symptoms for 50% of participants COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed the topline data shared today from an open-label study of psilocybin therapy for depression in cancer patients. Within one […]